Xenon Pharmaceuticals Inc.
Clinical trials sponsored by Xenon Pharmaceuticals Inc., explained in plain language.
-
New drug shows promise for Long-Term bipolar depression control
Disease control ENROLLING_BY_INVITATIONThis Phase 3 study tests the long-term safety and effectiveness of azetukalner, a daily pill, in 400 adults with bipolar I or II depression who previously completed a related study. Participants take the drug for 52 weeks, and researchers track side effects, mood changes, and qua…
Phase: PHASE3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New depression drug tested for Long-Term safety and effectiveness
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of azetukalner in adults with major depressive disorder. Participants must have successfully completed a previous phase 3 study of this drug. The goal is to monitor side effects and track changes in depression symptoms ov…
Phase: PHASE3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New epilepsy drug XEN1101 tested for long-term seizure control
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of XEN1101 (azetukalner) in 880 adults with focal or tonic-clonic seizures. Participants who completed earlier studies will take XEN1101 capsules for up to 6 years. Researchers will track side effects and changes in monthly …
Phase: PHASE3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC